- SPACs
- Lifesci Acquisition II Corp.
Lifesci Acquisition II Corp.
Completed 2021-10-06- CIK 1819113
- LSAQ
- Now SNCE
- IPO 2020-11-23
- $80.1M trust
- 284 filings
Successfully merged with Science 37, Inc. • Now trading as SNCE
- IPO Size
- $80.1M
- raised at the IPO
- Trust
- $80.1M
- as of 2021-09-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
284 filings over 15 quarters; violet bars carry a milestone
- 20 Q3: 1 filing
- 20 Q4: 26 filings
- 21 Q1: 5 filings
- 21 Q2: 7 filings
- 21 Q3: 16 filings
- 21 Q4: 57 filings
- 22 Q1: 21 filings
- 22 Q2: 24 filings
- 22 Q3: 17 filings
- 22 Q4: 13 filings
- 23 Q1: 15 filings
- 23 Q2: 26 filings
- 23 Q3: 7 filings
- 23 Q4: 9 filings
- 24 Q1: 40 filings
- S-1 filed 20 Q3
- IPO 20 Q4
- Definitive agreement 21 Q2
- Completed 21 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
- Registration2020-07-27 Filed S1
- IPO2020-11-23 IPO, search begins
- Definitive Agreement2021-05-06 Agreement for merger
- Completed2021-10-06 Merger Completed
About
LifeSci Acquisition II Corp. is a blank-check company formed to complete an initial business combination. It intends to target healthcare-innovation companies, including those developing biopharma, medical technology, digital health, and healthcare services assets.
Investment Focus
Biopharmaceuticals, Healthcare, Technology
Geographic Focus
North America, Europe
Key Information
As the filings state it
- IPO Date
- 2020-11-23
- Total Redemptions
- $23M
- PIPE
- $200M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-10-06
- Merger Target
- Science 37, Inc.
- SPAC Ticker
- LSAQ
- Merged Ticker
- SNCE
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team is led by Andrew McDonald and Michael Rice, co-founders of LifeSci Advisors and LifeSci Capital, and David Dobkin, managing director of LifeSci Capital. The filing describes the LifeSci team as having life-sciences investing and banking, scientific, medical, legal, and operational experience.